MSH2 and pancreatic neoplasm: However, other immunohistochemical patterns have been described in pancreatic cancer with loss of MSH2 but not MSH6 [18] and in Lynch syndrome, where the multitude of disease-predisposing mutations may have variable effects on epitope expression, from complete loss to weak or retained expression for one or both heterodimerizing proteins [32, 33].